|
Adachi, Y., Oshiro, T., Mori, M., Maehara, Y. and Sugimachi, K. (1997). Tumor size as a simple prognostic indicator for gastric carcinoma. Ann Surg Oncol, 4(2), 137-140.
Aishima, S. I., Taguchi, K. I., Sugimachi, K., Shimada, M., Sugimachi, K. and Tsuneyoshi, M. (2002). c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology, 40(3), 269-278.
Ajisaka, H., Shimizu, K. and Miwa, K. (2003). Immunohistochemical study of protein induced by vitamin K absence or antagonist II in hepatocellular carcinoma. J Surg Oncol, 84(2), 89-93.
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W. and Heiss, M. M. (2000). c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol, 18(11), 2201-2209.
American Society of Clinical Oncology. (1996). Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol, 14(2), 671-679.
Anderson, C. D., Pinson, C. W., Berlin, J. and Chari, R. S. (2004). Diagnosis and treatment of cholangiocarcinoma. Oncologist, 9(1), 43-57.
Bando, E., Kojima, N., Kawamura, T., Takahashi, S., Fukushima, N. and Yonemura, Y. (2004). Prognostic value of age and sex in early gastric cancer. Br J Surg, 91(9), 1197-1201.
Bedikian, A. Y., Chen, T. T., Khankhanian, N., Heilbrun, L. K., McBride, C. M., McMurtrey, M. J. and Bodey, G. P. (1984). The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol, 2(4), 305-310.
Bergsland, E. K. (2001). Molecular mechanisms underlying the development of hepatocellular carcinoma. Semin Oncol, 28(5), 521-531.
Bruix, J., Boix, L., Sala, M. and Llovet, J. M. (2004). Focus on hepatocellular carcinoma. Cancer Cell, 5(3), 215-219.
Bugat, R. (2003). Irinotecan in the treatment of gastric cancer. Ann Oncol, 14 Suppl 2, ii37-40.
Burke, E. C., Jarnagin, W. R., Hochwald, S. N., Pisters, P. W., Fong, Y. and Blumgart, L. H. (1998). Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg, 228(3), 385-394.
Cangialose, C. B., Blair, A. E., Borchardt, J. S., Ades, T. B., Bennett, C. L., Dickersin, K., Gesme, D. H., Jr., Henderson, I. C., McGinnis, L. S., Jr., Mooney, K., Mortenson, L. E., Sperduto, P., Winkenwerder, W., Jr. and
Ballard, D. J. (2000). Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services. Cancer, 88(12), 2876-2886.
Chang, K. J., Lin, J. K., Lee, P. H., Hsieh, Y. S., Cheng, C. K. and Liu, J. Y. (1996). The altered activity of membrane-bound protein kinase C in human liver cancer. Cancer Lett, 105(2), 211-215.
Chen, C. N., Sung, C. T., Lin, M. T., Lee, P. H. and Chang, K. J. (2001). Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann Surg, 233(2), 183-188.
Chen, C. N., Cheng, Y. M., Lin, M. T., Hsieh, F. J., Lee, P. H. and Chang, K. J. (2002). Association of color Doppler vascularity index and microvessel density with survival in patients with gastric cancer. Ann Surg, 235(4), 512-518.
Chen, C. N., Hsieh, F. J., Cheng, Y. M., Cheng, W. F., Su, Y. N., Chang, K. J. and Lee, P. H. (2004a). The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett, 213(1), 73-82.
Chen, C. N., Hsieh, F. J., Cheng, Y. M., Lee, P. H. and Chang, K. J. (2004b). Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome. J Surg Oncol, 86(1), 22-27.
Chen, C. N., Lin, J. J., Chen, J. J., Lee, P. H., Yang, C. Y., Kuo, M. L., Chang, K. J. and Hsieh, F. J. (2005). Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol, 23(29), 7286-7295.
Chen, M. F. (1999). Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol, 14(12), 1144-1149.
Chen, P. J. and Chen, D. S. (1999). Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin Liver Dis, 19(3), 253-262.
Chen, W. T., Chau, G. Y., Lui, W. Y., Tsay, S. H., King, K. L., Loong, C. C. and Wu, C. W. (2004). Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. Eur J Surg Oncol, 30(4), 414-420.
Chung, Y. C., Chang, K. J., Yang, C. C., Lai, M. T., Hsu, C. P., Hsueh, S. F., Peng, C. C., Fu, H. H., Chang, Y. F. and Yang, S. D. (2002). Association of proline-directed protein kinase FA with tumorigenesis, invasion, and poor prognosis of human colon carcinoma. Cancer, 95(9), 1840-1847.
Cohen, P. and Frame, S. (2001). The renaissance of GSK3. Nat Rev Mol Cell Biol, 2(10), 769-776.
Cox, D. R. (1972). Regression models and life tables. J R Stat Soc A, 29, 187-220.
Cusnir, M. and Patt, Y. Z. (2004). Novel systemic therapy options for hepatocellular carcinoma. Cancer J, 10(2), 97-103.
D'Ugo, D., Pacelli, F., Persiani, R., Pende, V., Ianni, A., Papa, V., Battista Doglietto, G. and Picciocchi, A. (2002). Impact of the latest TNM classification for gastric cancer: retrospective analysis on 94 D2 gastrectomies. World J Surg, 26(6), 672-677.
Date, K., Matsumoto, K., Kuba, K., Shimura, H., Tanaka, M. and Nakamura, T. (1998). Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene, 17(23), 3045-3054.
Diamantis, I., Karamitopoulou, E., Perentes, E. and Zimmermann, A. (1995). p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology, 22(3), 774-779.
Dicken, B. J., Bigam, D. L., Cass, C., Mackey, J. R., Joy, A. A. and Hamilton, S. M. (2005). Gastric adenocarcinoma: review and considerations for future directions. Ann Surg, 241(1), 27-39.
Dragovich, T., Rudin, C. M. and Thompson, C. B. (1998). Signal transduction pathways that regulate cell survival and cell death. Oncogene, 17(25), 3207-3213.
Edmonson, H. A. and Steiner, P. E. (1954). Primary carcinoma of the liver: a study of 100 among 489,000 necropsies. Cancer (Phila.), 7(3), 462-503.
El-Rifai, W. and Powell, S. M. (2002). Molecular biology of gastric cancer. Semin Radiat Oncol, 12(2), 128-140.
Embi, N., Rylatt, D. B. and Cohen, P. (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem, 107(2), 519-527.
Fiorentino, M., Altimari, A., D'Errico, A., Cukor, B., Barozzi, C., Loda, M. and Grigioni, W. F. (2000). Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res, 6(10), 3966-3972.
Fiorentino, M., Altimari, A., D'Errico, A., Gabusi, E., Chieco, P., Masetti, M. and Grigioni, W. F. (2001). Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. Clin Cancer Res, 7(12), 3994-3999.
Fondevila, C., Metges, J. P., Fuster, J., Grau, J. J., Palacin, A., Castells, A., Volant, A. and Pera, M. (2004). p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer, 90(1), 206-215.
Fong, Y., Sun, R. L., Jarnagin, W. and Blumgart, L. H. (1999). An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg, 229(6), 790-799; discussion 799-800.
Frame, S. and Cohen, P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem J, 359(Pt 1), 1-16.
Fu, H. H. (2004). The essential and critical roles of proline-directed protein kinase FA (PDPK FA) in human pancreatic ductal adenocarcinoma. Unpublished PhD thesis, National Tsing-Hua University, Taiwan, ROC.
Fu, H. H. and Yang, S. D. (2004). Suppression of proline-directed protein kinase FA inhibits the malignant growth of human pancreatic ductal adenocarcinoma. Anticancer Res, 24(3a), 1489-1494.
Fuchs, C. S. and Mayer, R. J. (1995). Gastric carcinoma. N Engl J Med, 333(1), 32-41.
Fukagawa, T., Sasako, M., Mann, G. B., Sano, T., Katai, H., Maruyama, K., Nakanishi, Y. and Shimoda, T. (2001). Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma. Cancer, 92(4), 753-760.
Ganne-Carrie, N. and Trinchet, J. C. (2004). Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 16(3), 275-281.
Gaspar, M. J., Arribas, I., Coca, M. C. and Diez-Alonso, M. (2001). Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol, 22(5), 318-322.
Gong, S. J., Jin, C. J., Rha, S. Y. and Chung, H. C. (2004). Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett, 214(2), 215-224.
Grau, J. J., Domingo-Domenech, J., Morente, V., Pera, M., Garcia-Valdecasas, J. C., Fuster, J., Bombi, A., Mellado, B., Albanell, J. and Gascon, P. (2004). Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur. Oncology, 66(3), 226-233.
He, X., Saint-Jeannet, J. P., Woodgett, J. R., Varmus, H. E. and Dawid, I. B. (1995). Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature, 374(6523), 617-622.
Heiss, M. M., Babic, R., Allgayer, H., Gruetzner, K. U., Jauch, K. W., Loehrs, U. and Schildberg, F. W. (1995). Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol, 13(8), 2084-2093.
Hemmings, B. A., Yellowlees, D., Kernohan, J. C. and Cohen, P. (1981). Purification of glycogen synthase kinase 3 from rabbit skeletal muscle. Copurification with the activating factor (FA) of the (Mg-ATP) dependent protein phosphatase. Eur J Biochem, 119(3), 443-451.
Ho, M. C., Wu, Y. M., Hu, R. H., Ko, W. J., Yang, P. M., Lai, M. Y., Lin, M. H., Lin, H. Y. and Lee, P. H. (2004). Liver transplantation for patients with hepatocellular carcinoma. Transplant Proc, 36(8), 2291-2292.
Hsu, H. C., Tseng, H. J., Lai, P. L., Lee, P. H. and Peng, S. Y. (1993). Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res, 53(19), 4691-4694.
Hsu, C., Huang, C. L., Hsu, H. C., Lee, P. H., Wang, S. J. and Cheng, A. L. (2002). HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer, 94(2), 415-420.
Hsu, C. P., Hsueh, S. F., Yang, C. C. and Yang, S. D. (2000a). Suppression of proline-directed protein kinase FA expression inhibits the growth of human chronic myeloid leukaemia cells. Br J Cancer, 82(8), 1480-1484.
Hsu, C. P., Yang, C. C. and Yang, S. D. (2000b). Suppression of proline-directed protein kinase FA expression potentiates erythroid differentiation of human myeloid leukemia cells. Cancer, 89(5), 1004-1011.
Hsu, H. C., Jeng, Y. M., Mao, T. L., Chu, J. S., Lai, P. L. and Peng, S. Y. (2000c). Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol, 157(3), 763-770.
Hsu, C. P., Yang, C. C., Hsueh, S. F., Peng, C. C., Fu, H. H. and Yang, S. D. (2001a). Suppression of proline-directed protein kinase FA potentiates apoptotic induction and greatly enhances chemosensitivity in human acute lymphoblastic leukemia cells. Cancer, 92(7), 1753-1758.
Hsu, C. P., Yang, C. C. and Yang, S. D. (2001b). Suppression of proline-directed protein kinase FA systemically inhibits the growth of human acute leukemia cells. Int J Cancer, 91(5), 650-653.
Hsu, Y. C., Fu, H. H., Jeng, Y. M., Lee, P. H., and Yang, S. D. (2006). Proline-directed protein kinase FA is a very powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J Clin Oncol, in press.
Hsueh, S. F., Lai, M. T., Yang, C. C., Chung, Y. C., Hsu, C. P., Peng, C. C., Fu, H. H., Cheng, Y. M., Chang, K. J. and Yang, S. D. (2002). Association of overexpressed proline-directed protein kinase FA with chemoresistance, invasion, and recurrence in patients with bladder carcinoma. Cancer, 95(4), 775-783.
Hu, R. H., Lee, P. H., Chang, Y. C., Ho, M. C. and Yu, S. C. (2003a). Treatment of centrally located hepatocellular carcinoma with central hepatectomy. Surgery, 133(3), 251-256.
Hu, R. H., Lee, P. H., Chang, Y. C., Yu, S. C., Ho, M. C. and Wu, Y. M. (2003b). Prognostic factors for hepatocellular carcinoma < or = 3 cm in diameter. Hepatogastroenterology, 50(54), 2043-2048.
Hu, T. H., Huang, C. C., Liu, L. F., Lin, P. R., Liu, S. Y., Chang, H. M., Changchien, C. S., Lee, C. M., Chuang, J. H. and Tai, M. H. (2003). Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer, 98(7), 1444-1456.
Huang, G. T., Lee, P. H., Tsang, Y. M., Lai, M. Y., Yang, P. M., Hu, R. H., Chen, P. J., Kao, J. H., Sheu, J. C., Lee, C. Z. and Chen, D. S. (2005). Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg, 242(1), 36-42.
Ilson, D. H. (2001). Adjuvant therapy for noncolorectal cancers. Curr Opin Oncol, 13(4), 287-290.
Ito, R., Nakayama, H., Yoshida, K., Matsumura, S., Oda, N. and Yasui, W. (2004). Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma. Virchows Arch, 444(4), 324-331.
Ito, Y., Takeda, T., Sakon, M., Monden, M., Tsujimoto, M. and Matsuura, N. (2000a). Expression and clinical significance of the G1-S modulators in carcinoma of the extrahepatic bile duct. Anticancer Res, 20(1A), 337-344.
Ito, Y., Takeda, T., Sakon, M., Tsujimoto, M. and Matsuura, N. (2000b). Expression and clinical implications of bcl-2 in extrahepatic bile duct carcinoma: its relationship with biological features. Anticancer Res, 20(5C), 3891-3895.
Itoh, S., Maeda, T., Shimada, M., Aishima, S., Shirabe, K., Tanaka, S. and Maehara, Y. (2004). Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res, 10(8), 2812-2817.
Jaeck, D., Bachellier, P., Oussoultzoglou, E., Weber, J. C. and Wolf, P. (2004). Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview. Liver Transpl, 10(2 Suppl 1), S58-63.
Jan, Y. Y., Yeh, C. N., Yeh, T. S. and Chen, T. C. (2005a). Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol, 11(12), 1779-1784.
Jan, Y. Y., Yeh, C. N., Yeh, T. S., Hwang, T. L. and Chen, M. F. (2005b). Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg, 29(7), 894-898.
Jarnagin, W. R., Klimstra, D. S., Hezel, M., Gonen, M., Fong, Y., Roggin, K., Cymes, K., DeMatteo, R. P., D'Angelica, M., Blumgart, L. H. and Singh, B. (2006). Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol, 24(7), 1152-1160.
Jauch, K. W., Heiss, M. M., Gruetzner, U., Funke, I., Pantel, K., Babic, R., Eissner, H. J., Riethmueller, G. and Schildberg, F. W. (1996). Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol, 14(6), 1810-1817.
Jeng, Y. M., Peng, S. Y., Lin, C. Y. and Hsu, H. C. (2004). Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res, 10(6), 2065-2071.
Kaplan, E. L. and Meier, P. (1958). Non parametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457-481.
Karin, M. (1991). Signal transduction and gene control. Curr Opin Cell Biol, 3(3), 467-473.
Karpeh, M. S., Jr. and Brennan, M. F. (1994). Progress in the management of gastric cancer. Curr Opin Gen Surg, 125-130.
Khan, S. A., Thomas, H. C., Davidson, B. R. and Taylor-Robinson, S. D. (2005). Cholangiocarcinoma. Lancet, 366, 1303-1314.
Kikuchi, S., Sakakibara, Y., Sakuramoto, S., Kobayashi, N., Shimao, H., Mieno, H., Kato, Y., Kadowaki, K., Hiki, Y. and
Kakita, A. (2001). Recent results in the surgical treatment of gastric cancer according to the Japanese and TNM classification. Anticancer Res, 21(5), 3589-3593.
King, K. L., Li, A. F., Chau, G. Y., Chi, C. W., Wu, C. W., Huang, C. L. and Liu, W. Y. (2000). Prognostic significance of heat shock protein-27 expression in hepatocellular carcinoma and its relation to histologic grading and survival. Cancer, 88(11), 2464-2470.
Kitagawa, Y., Nagino, M., Kamiya, J., Uesaka, K., Sano, T., Yamamoto, H., Hayakawa, N. and Nimura, Y. (2001). Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg, 233(3), 385-392.
Klempnauer, J., Ridder, G. J., Werner, M., Weimann, A. and Pichlmayr, R. (1997). What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer, 79(1), 26-34.
Klempnauer, J., Ridder, G. J., von Wasielewski, R., Werner, M., Weimann, A. and Pichlmayr, R. (1997). Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol, 15(3), 947-954
Kumar, R. and Hung, M. C. (2005). Signaling intricacies take center stage in cancer cells. Cancer Res, 65(7), 2511-2515.
Lage, H. (2003). Molecular analysis of therapy resistance in gastric cancer. Dig Dis, 21(4), 326-338.
Lau, K. F., Miller, C. C., Anderton, B. H. and Shaw, P. C. (1999a). Expression analysis of glycogen synthase kinase-3 in human tissues. J Pept Res, 54(1), 85-91.
Lau, K. F., Miller, C. C., Anderton, B. H. and Shaw, P. C. (1999b). Molecular cloning and characterization of the human glycogen synthase kinase-3 beta promoter. Genomics, 60(2), 121-128.
Lazaridis, K. N. and Gores, G. J. (2005). Cholangiocarcinoma. Gastroenterology, 128, 1655-67.
Lee, K. F., Chan, J. Y., Lau, K. F., Lee, W. C., Miller, C. C., Anderton, B. H. and Shaw, P. C. (2000). Molecular cloning and expression analysis of human glycogen synthase kinase-3 alpha promoter. Brain Res Mol Brain Res, 84(1-2), 150-157.
Lee, P. H., Lin, W. J., Tsang, Y. M., Hu, R. H., Sheu, J. C., Lai, M. Y., Hsu, H. C., May, W. and Lee, C. S. (1995a). Clinical management of recurrent hepatocellular carcinoma. Ann Surg, 222(5), 670-676.
Lee, W. J., Lee, P. H., Yue, S. C., Chang, K. C., Wei, T. C. and Chen, K. M. (1995b). Lymph node metastases in gastric cancer: significance of positive number. Oncology, 52(1), 45-50.
Lee, W. J., Lee, W. C., Houng, S. J., Shun, C. T., Houng, R. L., Lee, P. H., Chang, K. J., Wei, T. C. and Chen, K. M. (1995c). Survival after resection of gastric cancer and prognostic relevance of systematic lymph node dissection: twenty years experience in Taiwan. World J Surg, 19(5), 707-713.
Lee, W. C., Jeng, L. B. and Chen, M. F. (2002). Estimation of prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg, 89(3), 311-316.
Limpaiboon, T., Krissadarak, K., Sripa, B., Jearanaikoon, P., Bhuhisawasdi, V., Chau-in, S., Romphruk, A. and Pairojkul, C. (2002). Microsatellite alterations in liver fluke related cholangiocarcinoma are associated with poor prognosis. Cancer Lett, 181(2), 215-222.
Lin, M. T., Wang, M. Y., Liaw, K. Y., Lee, P. H., Chien, S. F., Tsai, J. S. and Lin-Shiau, S. Y. (2001). Superoxide dismutase in hepatocellular carcinoma affects patient prognosis. Hepatogastroenterology, 48(40), 1102-1105.
Lin, S. M., Lin, C. J., Hsu, C. W., Tai, D. I., Sheen, I. S., Lin, D. Y. and Liaw, Y. F. (2003). Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer, 100(2), 376-382.
Liu, S. H., Lin, C. Y., Peng, S. Y., Jeng, Y. M., Pan, H. W., Lai, P. L., Liu, C. L. and Hsu, H. C. (2002). Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol, 160(5), 1831-1837.
Liver Cancer Study Group of Japan. (1994). Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer, 74(10), 2772-2780.
Llovet, J. M. (2005). Updated treatment approach to hepatocellular carcinoma. J Gastroenterol, 40(3), 225-235.
Maehara, Y., Kakeji, Y., Oda, S., Baba, H. and Sugimachi, K. (2001). Tumor growth patterns and biological characteristics of early gastric carcinoma. Oncology, 61(2), 102-112.
Maehara, Y., Oshiro, T., Endo, K., Baba, H., Oda, S., Ichiyoshi, Y., Kohnoe, S. and Sugimachi, K. (1996). Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery, 119(4), 397-402.
Malats, N., Porta, M., Pinol, J. L., Corominas, J. M., Rifa, J. and Real, F. X. (1995). Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer. PANK-ras I Project Investigators. J Clin Oncol, 13(7), 1679-1686.
Manoukian, A. S. and Woodgett, J. R. (2002). Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res, 84, 203-229.
Martinez, A., Castro, A., Dorronsoro, I. and Alonso, M. (2002). Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev, 22(4), 373-384.
Nevalainen, M. T., Xie, J., Torhorst, J., Bubendorf, L., Haas, P., Kononen, J., Sauter, G. and Rui, H. (2004). Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol, 22(11), 2053-2060.
Novina, C. D. and Roy, A. L. (1996). Core promoters and transcriptional control. Trends Genet, 12(9), 351-355.
Okada, Y., Fujiwara, Y., Yamamoto, H., Sugita, Y., Yasuda,
T., Doki, Y., Tamura, S., Yano, M., Shiozaki, H., Matsuura, N. and Monden, M. (2001). Genetic detection of lymph node micrometastases in patients with gastric carcinoma by multiple-marker reverse transcriptase-polymerase chain reaction assay. Cancer, 92(8), 2056-2064.
Olnes, M. J. and Erlich, R. (2004). A review and update on cholangiocarcinoma. Oncology, 66(3), 167-179.
Oshikiri, T., Miyamoto, M., Shichinohe, T., Suzuoki, M., Hiraoka, K., Nakakubo, Y., Shinohara, T., Itoh, T., Kondo, S. and Katoh, H. (2003). Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol, 84(4), 224-228.
Pan, H. W., Ou, Y. H., Peng, S. Y., Liu, S. H., Lai, P. L., Lee, P. H., Sheu, J. C., Chen, C. L. and Hsu, H. C. (2003). Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 98(1), 119-127.
Parkin, D. M., Pisani, P. and Ferlay, J. (1999). Global cancer statistics. CA Cancer J Clin, 49(1), 33-64, 31.
Pearson, M. L., Ganz, P. A., McGuigan, K., Malin, J. R., Adams, J. and Kahn, K. L. (2002). The case identification challenge in measuring quality of cancer care. J Clin Oncol, 20(21), 4353-4360.
Peto, R. and Peto, J. (1972). Asymptotically efficient invariant procedures. J R Stat Soc A, 135, 185-206.
Pinto-De-Sousa, J., David, L., Seixas, M. and Pimenta, A. (2001). Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. Dig Surg, 18(2), 102-110.
Pitt, H. A., Nakeeb, A., Abrams, R. A., Coleman, J., Piantadosi, S., Yeo, C. J., Lillemore, K. D. and Cameron, J. L. (1995). Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg, 221(6), 788-797; discussion 797-788.
Plyte, S. E., Hughes, K., Nikolakaki, E., Pulverer, B. J. and Woodgett, J. R. (1992). Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta, 1114(2-3), 147-162.
Poon, R. T. and Fan, S. T. (2004). Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl, 10(2 Suppl 1), S39-45.
Poon, R. T., Fan, S. T. and Wong, J. (2000). Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg, 232(1), 10-24.
Poon, R. T., Lau, C. P., Ho, J. W., Yu, W. C., Fan, S. T. and Wong, J. (2003). Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res, 9(14), 5339-5345.
Qin, L. X. and Tang, Z. Y. (2002). The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol, 8(2), 193-199.
Qin, L. X. and Tang, Z. Y. (2004). Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol, 130(9), 497-513.
Reichlin, M. (1980). Use of glutaraldehyde as a coupling agent for proteins and peptides. Methods Enzymol, 70(A), 159-165.
Saito, H. and Tsujitani, S. (2001). Angiogenesis, angiogenic factor expression and prognosis of gastric carcinoma. Anticancer Res, 21(6B), 4365-4372.
Sano, T., Sasako, M., Kinoshita, T. and Maruyama, K. (1993). Recurrence of early gastric cancer. Follow-up of 1475 patients and review of the Japanese literature. Cancer, 72(11), 3174-3178.
Scartozzi, M., Galizia, E., Freddari, F., Berardi, R., Cellerino, R. and Cascinu, S. (2004). Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev, 30(5), 451-459.
Schoniger-Hekele, M., Hanel, S., Wrba, F. and Muller, C. (2005). Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int, 25(1), 62-69.
Schwartz, G. K. (1996). Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol, 23(3), 316-324.
Shaw, P. C., Davies, A. F., Lau, K. F., Garcia-Barcelo, M., Waye, M. M., Lovestone, S., Miller, C. C. and Anderton, B. H. (1998). Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and -3 beta encoding genes. Genome, 41(5), 720-727.
Shimada, Y., Yamasaki, S., Hashimoto, Y., Ito, T., Kawamura, J., Soma, T., Ino, Y., Nakanishi, Y., Sakamoto, M., Hirohashi, S. and Imamura, M. (2004). Clinical significance of dysadherin expression in gastric cancer patients. Clin Cancer Res, 10(8), 2818-2823.
Sirica, A. E., Lai, G. H. and Zhang, Z. (2001). Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol, 16(4), 363-372.
Sirica, A. E., Lai, G. H., Endo, K., Zhang, Z. and Yoon, B. I. (2002). Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis, 22(3), 303-313.
Sirica, A. E. (2005). Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology, 41(1), 5-15.
Sobin, L. H. and Fleming, I. D. (1997). TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer, 80(9), 1803-1804.
Stacker, S. A., Achen, M. G., Jussila, L., Baldwin, M. E. and Alitalo, K. (2002). Lymphangiogenesis and cancer metastasis. Nat Rev Cancer, 2(8), 573-583.
Starzynska, T., Markiewski, M., Domagala, W., Marlicz, K., Mietkiewski, J., Roberts, S. A. and Stern, P. L. (1996). The clinical significance of p53 accumulation in gastric carcinoma. Cancer, 77(10), 2005-2012.
Sun, W. and Haller, D. G. (2001). Recent advances in the treatment of gastric cancer. Drugs, 61(11), 1545-1551.
Suriawinata, A. and Xu, R. (2004). An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis, 24, 77-88.
Suzuki, M. (1989). SPXX, a frequent sequence motif in gene regulatory proteins. J Mol Biol, 207(1), 61-84.
Suzuoki, M., Hida, Y., Miyamoto, M., Oshikiri, T., Hiraoka, K., Nakakubo, Y., Shinohara, T., Itoh, T., Okushiba, S., Kondo, S. and Katoh, H. (2002). RCAS1 expression as a prognostic factor after curative surgery for extrahepatic bile duct carcinoma. Ann Surg Oncol, 9(4), 388-393.
Tahara, E. (1993). Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol, 119(5), 265-272.
Tas, F., Aykan, N. F., Aydiner, A., Uygun, K., Basaran, M., Camlica, H. and Topuz, E. (2000). The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival. Am J Clin Oncol, 23(1), 53-57.
Thomas, M. B. and Zhu, A. X. (2005). Hepatocellular carcinoma: the need for progress. J Clin Oncol, 23(13), 2892-2899.
Tsujitani, S., Saito, H., Maeta, Y., Yamaguchi, K., Tatebe, S., Kondo, A. and Kaibara, N. (2004). Neoangiogenesis in patients with gastric carcinoma in relation to the expression of vascular endothelial growth factor and thymidine phosphorylase. Anticancer Res, 24(3b), 1853-1859.
Van Deusen, M. A., Abdalla, E. K., Vauthey, J. N. and Roh,
M. S. (2005). Staging classifications for hepatocellular carcinoma. Expert Rev Mol Diagn, 5(3), 377-383.
Vandenheede, J. R., Yang, S. D., Goris, J. and Merlevede, W. (1980). ATP•Mg-dependent protein phosphatase from rabbit skeletal muscle. II. Purification of the activating factor and its characterization as a bifunctional protein also displaying synthase kinase activity. J Biol Chem, 255(24), 11768-11774.
Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. Embo J, 9(8), 2431-2438.
Woodgett, J. R. (2003). Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr Drug Targets Immune Endocr Metabol Disord, 3(4), 281-290.
Yamamoto, H., Horiuchi, S., Adachi, Y., Taniguchi, H., Nosho, K., Min, Y. and Imai, K. (2004). Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. Carcinogenesis, 25(3), 325-332.
Yamamoto, S., Tomita, Y., Hoshida, Y., Takiguchi, S., Fujiwara, Y., Yasuda, T., Yano, M., Nakamori, S., Sakon, M., Monden, M. and Aozasa, K. (2003a). Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. J Clin Oncol, 21(13), 2537-2544.
Yamamoto, S., Tomita, Y., Nakamori, S., Hoshida, y., Nagano, H., Dono, K., Umeshita, K., sakon, M., Monden, M. and Aozasa, K. (2003b). Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. J Clin Oncol, 21(3), 447-452.
Yamanaka, N., Sasaki, N., Tasaki, A., Nakashima, H., Kubo, M., Morisaki, T., Noshiro, H., Yao, T., Tsuneyoshi, M., Tanaka, M. and Katano, M. (2004). Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma. Anticancer Res, 24(2C), 1071-1075.
Yang, C. C., Hsu, C. P. and Yang, S. D. (2000). Antisense suppression of proline-directed protein kinase FA enhances chemosensitivity in human prostate cancer cells. Clin Cancer Res, 6(3), 1024-1030.
Yang, S. D. (1986). Identification of the ATP.Mg-dependent protein phosphatase activator (FA) as a myelin basic protein kinase in the brain. J Biol Chem, 261(25), 11786-11791.
Yang, S. D. (1991). Characteristics and regulation of the ATP.Mg-dependent protein phosphatase activating factor (protein kinase FA). Adv. Prot. Phosphatase, 6, 133-157 (EMBO-FEBS Invited Review).
Yang, S. D. (1994). Signal transduction and biological functions of protein phosphatase activating factor (protein kinase FA/GSK-3alpha). J. Chin. Biochem. Soc., 23, 123-134 (Invited Review).
Yang, S. D. (2004). Proline-directed protein kinase FA as a potential target for diagnosis and therapy of human cancers. Curr Cancer Drug Targets, 4(7), 591-596 (Invited Review).
Yang, S. D. (2005). Proline-directed protein kinase FA as a new signal transducing target for lethal cancer treatment. Drug News Perspect, 18(7), 432-436 (Invited Review).
Yang, S. D., Huang, J. J. and Huang, T. J. (1995a). Protein kinase FA/glycogen synthase kinase 3 alpha predominantly phosphorylates the in vivo sites of Ser502, Ser506, Ser603, and Ser666 in neurofilament. J Neurochem, 64(4), 1848-1854.
Yang, S. D., Yu, J. S., Lee, T. T., Ni, M. H., Yang, C. C., Ho, Y. S. and Tsen, T. Z. (1995b). Association of protein kinase FA/GSK-3alpha (a proline-directed kinase and a regulator of protooncogenes) with human cervical carcinoma dedifferentiation/progression. J Cell Biochem, 59(2), 143-150.
Yang, S. D., Song, J. S., Yu, J. S. and Shiah, S. G. (1993). Protein kinase FA/GSK-3 phosphorylates tau on Ser235-Pro and Ser404-Pro that are abnormally phosphorylated in Alzheimer's disease brain. J Neurochem, 61(5), 1742-1747.
Yang, S. D., Vandenheede, J. R., Goris, J. and Merlevede, W. (1980). ATP•Mg-dependent protein phosphatase from rabbit skeletal muscle. I. Purification of the enzyme and its regulation by the interaction with an activating protein factor. J Biol Chem, 255(24), 11759-11767.
Yang, S. D., Yu, J. S., Shiah, S. G. and Huang, J. J. (1994). Protein kinase FA/glycogen synthase kinase-3 alpha after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain. J Neurochem, 63(4), 1416-1425.
Yang, S. D., Yu, J. S., Yang, C. C., Lee, S. C., Lee, T. T., Ni, M. H., Kuan, C. Y. and Chen, H. C. (1996). Overexpression of protein kinase FA/GSK-3 alpha (a proline-directed protein kinase) correlates with human hepatoma dedifferentiation/progression. J Cell Biochem, 61(2), 238-245.
Yasui, W., Oue, N., Aung, P. P., Matsumura, S., Shutoh, M. and Nakayama, H. (2005). Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer, 8(2), 86-94.
Yokota, T., Ishiyama, S., Saito, T., Teshima, S., Yamada, Y., Iwamoto, K., Takahashi, M., Murata, K. and Yamauchi, H. (2002). Is tumor size a prognostic indicator for gastric carcinoma? Anticancer Res, 22(6B), 3673-3677.
Yu, J. S. and Yang, S. D. (1994). Protein kinase FA/glycogen synthase kinase-3 predominantly phosphorylates the in vivo site Thr97-Pro in brain myelin basic protein: evidence for Thr-Pro and Ser-Arg-X-X-Ser as consensus sequence motifs. J Neurochem, 62(4), 1596-1603.
Yuan, R. H., Jeng, Y. M., Chen, H. L., Hsieh, F. J., Yang, C. Y., Lee, P. H. and Hsu, H. C. (2005). Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis. Clin Cancer Res, 11(7), 2568-2575.
Zhu, A. X. (2003). Hepatocellular carcinoma: are we making progress? Cancer Invest, 21(3), 418-428.
|